IDWeek 2022
Drugs of the Future
; 48(1):63-67, 2023.
Article
in English
| EMBASE | ID: covidwho-2317670
ABSTRACT
IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP). For the first time since the COVID-19 public health emergency began, IDWeek 2022 returned to in-person attendance. It was held in Washington, D.C., and the meeting comprised 5 days of live sessions and on-demand content that included posters and oral presentations.Copyright © 2023 Clarivate.
Adintrevimab; brii-732; Ensovibep; ExPEC10V; rbx-2660; spr-206; adult; atypical mycobacteriosis/dt [Drug Therapy]; bactericidal activity; Clostridium difficile infection/dt [Drug Therapy]; comorbidity; conference paper; consensus development; coronavirus disease 2019/dt [Drug Therapy]; cytomegalovirus infection/dt [Drug Therapy]; cytomegalovirus infection/pc [Prevention]; dermatophytosis/dt [Drug Therapy]; disease severity; drug repositioning; early intervention; emergency; epidemiologist; Escherichia coli infection/dt [Drug Therapy]; Escherichia coli infection/pc [Prevention]; extraintestinal pathogenic Escherichia coli; group B streptococcal infection/dt [Drug Therapy]; group B streptococcal infection/pc [Prevention]; human; immune response; infection; lung infection/dt [Drug Therapy]; medical society; medicine; mouse model; multidrug resistant infection/dt [Drug Therapy]; nonhuman; normal human; pharmacist; phase 1 clinical trial (topic); public health service; recurrent infection/dt [Drug Therapy]; serotype; vaccine immunogenicity; virus load; Washington; Zika fever/dt [Drug Therapy]; Zika fever/pc [Prevention]; adintrevimab/dt [Drug Therapy]; alexidine/dt [Drug Therapy]; anti human immunodeficiency virus agent/ct [Clinical Trial]; anti-SARS-CoV-2 agent/dt [Drug Therapy]; antibiotic agent/dt [Drug Therapy]; bacterial polysaccharide/dt [Drug Therapy]; conjugate vaccine/dt [Drug Therapy]; Cytomegalovirus vaccine/dt [Drug Therapy]; ensovibep/ct [Clinical Trial]; ensovibep/dt [Drug Therapy]; epetraborole/dt [Drug Therapy]; Escherichia coli vaccine/dt [Drug Therapy]; lipid nanoparticle/dt [Drug Therapy]; microbial products not classified elsewhere/dt [Drug Therapy]; O antigen/dt [Drug Therapy]; polymyxin derivative/dt [Drug Therapy]; prodrug/ct [Clinical Trial]; RNA directed DNA polymerase inhibitor/ct [Clinical Trial]; RNA vaccine/dt [Drug Therapy]; Streptococcus vaccine/dt [Drug Therapy]; unclassified drug; Zika virus vaccine/dt [Drug Therapy]; brii 732/ct [Clinical Trial]; d 4d 30 713/dt [Drug Therapy]; gbs 6/dt [Drug Therapy]; gsk 052; mrna 1647; mrna 1647/dt [Drug Therapy]; pf 06760805; pr 020/dt [Drug Therapy]; rebiotix/dt [Drug Therapy]; rzikv/dt [Drug Therapy]; spr 206/dt [Drug Therapy]; vac 52416/dt [Drug Therapy]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Drugs of the Future
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS